Innate Pharma's Lacutamab IND Trials On Partial Hold By FDA After Severe Adverse Reaction; Phase 2 TELLOMAK Final Data Expected Q4 2023
Portfolio Pulse from Benzinga Newsdesk
The FDA has placed Innate Pharma's Lacutamab IND trials on partial hold due to a severe adverse reaction. The final data from the Phase 2 TELLOMAK trial is expected in Q4 2023.
October 05, 2023 | 6:40 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Innate Pharma's Lacutamab IND trials have been put on partial hold by the FDA due to a severe adverse reaction, potentially delaying the drug's development and approval process.
The FDA's decision to put Innate Pharma's Lacutamab IND trials on hold due to a severe adverse reaction could potentially delay the drug's development and approval process. This could negatively impact the company's stock price in the short term as it may lead to increased costs and delayed revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100